Skip to main content
SpringerLink
Log in

Inhaled Corticosteroids, Bone Mineral Density and Fracture in Older People

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The efficacy of inhaled corticosteroids in the treatment of asthma has been firmly established in a variety of settings. The majority of asthma management plans now recommend the use of inhaled corticosteroids at an early stage. This means that most patients with asthma will be prescribed an inhaled corticosteroid at some point in time and many patients with asthma will use these drugs for several years.

Inhaled corticosteroids are also used in the treatment of other conditions, particularly chronic obstructive pulmonary disease (COPD). Since inhaled corticosteroids are absorbed into the systemic circulation, they can have systemic adverse effects, such as suppression of the hypothalamic-pituitary-adrenal axis and increasing the risk of bruising. However, perhaps the greatest concern for patients is whether the regular use of inhaled corticosteroids has an adverse impact on the bone mineral density and increases the risk of fracture. There is now accumulating evidence from epidemiological studies that the use of inhaled corticosteroids is inversely related to bone mineral density in a dose-dependent fashion. However, data from two clinical trials of moderately high doses of inhaled corticosteroids in patients with COPD have produced conflicting results and while the larger study of triamcinolone found a significant impact of this drug on bone mineral density, a smaller study of budesonide found no effect.

Epidemiological research into the relationship between inhaled corticosteroids and fracture is at an early stage. To date, only three studies in this area have been reported, all of which have used different approaches to try to minimise the impact of bias and confounding. There is a lack of consistency between the final estimates of the impact of inhaled corticosteroids on fracture risk. However, taken together these data suggest that the short to medium term use of inhaled corticosteroids is associated with a small adverse effect on bone. Doctors and patients need to be aware of this risk and balance it against the known beneficial effects of inhaled corticosteroids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

Similar content being viewed by others

References

  1. Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. BMJ 1972; I: 585–90

    Article  Google Scholar 

  2. Clark TJH. Effect of beclomethasone dipropionate delivered by aerosol in patients with asthma. Lancet 1972; I: 1361–4

    Article  Google Scholar 

  3. British Thoracic and Tuberculosis Association. Inhaled corticosteroids compared with oral prednisolone in patients starting long term corticosteroid therapy for asthma. Lancet 1975; II: 469–73

    Google Scholar 

  4. Maberly DJ, Gibson GJ, Butler AG. Recovery of adrenal function after substitution of beclomethasone dipropionate for oral corticosteroids. BMJ 1973; I: 778–82

    Article  Google Scholar 

  5. Haahtela T, Jarvinen M, Kava T, et al. Comparison of beta-2 agonist terbutaline with an inhaled corticosteroid budesonide in newly detected asthma. N Engl J Med 1991; 325: 338–92

    Article  Google Scholar 

  6. Pauwels R, Lofdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405–11

    Article  PubMed  CAS  Google Scholar 

  7. Pauwels R, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361: 1071–6

    Article  PubMed  CAS  Google Scholar 

  8. Janson C, Chinn S, Jarvis D, et al. Physician diagnosed asthma and drug utilisation in the European Community Respiratory Health Survey. Eur Respir J 1997; 10: 1795–802

    Article  PubMed  CAS  Google Scholar 

  9. Roberts SJ, Bateman DN. Which patients are prescribed inhaled anti-asthma drugs? Thorax 1994; 49: 1090–5

    Article  PubMed  CAS  Google Scholar 

  10. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–303

    Article  PubMed  CAS  Google Scholar 

  11. Pauwels R, Lofdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue to smoke. N Engl J Med 1999; 340: 1948–53

    Article  PubMed  CAS  Google Scholar 

  12. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902–9

    Article  Google Scholar 

  13. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819–23

    Article  PubMed  CAS  Google Scholar 

  14. Donnelly R, Williams KM, Baker AB, et al. Effects of budesonide and fluticasone on 24-hour plasma cortisol. Am J Respir Crit Care Med 1997; 156: 1746–51

    PubMed  CAS  Google Scholar 

  15. Kerrebijn KF. Use of topical corticosteroids in the treatment of childhood asthma. Am Rev Respir Dis 1990; 141: S77–81

    PubMed  CAS  Google Scholar 

  16. Toogood JH, Lefcoe MS, Haines DSM, et al. A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol 1997; 59: 298–308

    Article  Google Scholar 

  17. Bisgaard H, Nielsen MD, Anderssen B, et al. Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide. J Allergy Clin Immunol 1988; 81: 1088–95

    Article  PubMed  CAS  Google Scholar 

  18. Jennings BH, Andersson KE, Johansson SA. Assessment of systemic effects of inhaled corticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1990; 40: 77–82

    Article  Google Scholar 

  19. Toogood JH, Baskerville JC, Jennings B, et al. Bioequivalent doses of budesonide and prednisolone in moderate and severe asthma. J Allergy Clin Immunol 1989; 84: 688–700

    Article  PubMed  CAS  Google Scholar 

  20. Harrison TW, Wisniewski A, Honour J, et al. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 2001; 56: 186–91

    Article  PubMed  CAS  Google Scholar 

  21. Boorsma M, Andersson N, Larsson P, et al. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 1996; 9: 1427–32

    Article  PubMed  CAS  Google Scholar 

  22. Harrison TW. Systemic availability of inhaled budesonide and fluticasone propionate: healthy versus asthmatic lungs. Bio-drugs 2001; 15: 405–11

    CAS  Google Scholar 

  23. Todd GR, Acerini CL, Buck JJ, et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone dipropionate. Eur Respir J 2002; 19: 1207–9

    Article  PubMed  CAS  Google Scholar 

  24. Todd GR, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87: 457–61

    Article  PubMed  CAS  Google Scholar 

  25. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and risk of cataracts. N Engl J Med 1997; 337: 8–14

    Article  PubMed  CAS  Google Scholar 

  26. Smeeth L, Boulis M, Hubbard R, et al. A population based case-control study of cataract and inhaled corticosteroids. Br J Ophthamol 2003; 87(10): 1247–51

    Article  CAS  Google Scholar 

  27. Garbe E, Lelorier J, Boivin J-F, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 722–7

    Article  PubMed  CAS  Google Scholar 

  28. Jennings BH, Andersson KE, Johansson SA. Assessment of systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone in adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1991; 40: 77–82

    Article  PubMed  CAS  Google Scholar 

  29. Toogood JH, Jennings B, Hodsman AB, et al. Effects of dose and dosing schedule of inhaled budesonide on bone turnover. J Allergy Clin Immunol 1991; 88: 572–80

    Article  PubMed  CAS  Google Scholar 

  30. Pouw EM, Prummell MF, Oosting H, et al. Beclomethasone inhalation decreases serum osteocalcin concentrations. BMJ 1991; 302: 627–8

    Article  PubMed  CAS  Google Scholar 

  31. Meeran K, Hattersley A, Burrin J, et al. Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. Am J Respir Crit Care Med 1995; 151: 333–6

    PubMed  CAS  Google Scholar 

  32. Ali NJ, Capewell S, Ward MJ. Bone turnover during high dose inhaled corticosteroid treatment. Thorax 1991; 46: 160–4

    Article  PubMed  CAS  Google Scholar 

  33. Birkebaek NH, Esberg G, Andersen K, et al. Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate. Arch Dis Child 1995; 73: 524–7

    Article  PubMed  CAS  Google Scholar 

  34. Kerstjen HAM, Postma DS, van Doormaal JJ, et al. Effects of short term and long term treatment with inhaled corticosteroids on bone metabolism in patients with airflow obstruction. Thorax 1994; 49: 652–6

    Article  Google Scholar 

  35. Jones A, Fay JK, Burr M, et al. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease (Cochrane Review). Available in The Coch-rane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 2003

    Google Scholar 

  36. Hanania NA, Chapman KR, Sturtridge WC, et al. Dose-related decrease in bone mineral density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995; 96: 571–9

    Article  PubMed  CAS  Google Scholar 

  37. Marystone JF, Barrett-Connor EL, Morton DJ. Inhaled and oral corticosteroids: their effect on bone mineral density in older adults. Am J Public Health 1995; 85: 1693–5

    Article  PubMed  CAS  Google Scholar 

  38. Laatikainen AK, Kroger HPJ, Tukiainen HO, et al. Bone mineral density in perimenopausal women with asthma. Am J Respir Crit Care Med 1999; 159: 1179–85

    PubMed  CAS  Google Scholar 

  39. Ip M, Lam K, Yam L, et al. Decreased bone mineral density in premenopausal asthmatic patients receiving long term inhaled steroids. Chest 1994; 105: 1722–7

    Article  PubMed  CAS  Google Scholar 

  40. Wisniewski AF, Lewis SA, Green DJ, et al. Cross sectional investigation of the effects of inhaled corticosteroids on bone mineral density and bone metabolism in patients with asthma. Thorax 1997; 52: 853–60

    Article  PubMed  CAS  Google Scholar 

  41. Toogood JH, Baskerville JC, Markov AE, et al. Bone mineral density and the risk of fracture in patients receiving long term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995; 96: 157–66

    Article  PubMed  CAS  Google Scholar 

  42. Harris M, Hauser S, Nguyen TV, et al. Bone mineral density in prepubertal asthmatics receiving corticosteroid treatment. J Paediatr Child Health 2001; 37: 67–71

    Article  PubMed  CAS  Google Scholar 

  43. Lau ECM, Li M, Woo J, et al. Bone mineral density and body composition in patients with airflow obstruction: the role of inhaled steroid therapy, disease and lifestyle. Clin Exp Allergy 1998; 28: 1066–71

    Article  PubMed  CAS  Google Scholar 

  44. Packe GE, Robb O, Robins SP, et al. Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate. J R Coll Physicians Lond 1996; 30: 128–32

    PubMed  CAS  Google Scholar 

  45. Packe GE, Douglas JG, McDonald AF, et al. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax 1992; 47: 414–7

    Article  PubMed  CAS  Google Scholar 

  46. Elmstahl S, Ekstrom H, Galvard H, et al. Is there an association between inhaled corticosteroids and bone density in postmeno-pausal women? J Allergy Clin Immunol 2003; 111: 91–6

    Article  PubMed  CAS  Google Scholar 

  47. Reilly SM, Hambleton G, Adams JE, et al. Bone density in asthmatic children treated with inhaled corticosteroids. Arch Dis Child 2001; 84: 183–4

    Article  PubMed  CAS  Google Scholar 

  48. Kinberg KA, Hopp RJ, Biven RE, et al. Bone mineral density in normal and asthmatic children. J Allergy Clin Immunol 1994; 94: 490–7

    Article  PubMed  CAS  Google Scholar 

  49. Wolff AH, Adelsberg B, Aloia J, et al. Effect of inhaled corticosteroid on bone density in asthmatic patients: a pilot study. Ann Allergy 1991; 67: 117–21

    PubMed  CAS  Google Scholar 

  50. Herrala J, Puolijoki H, Impivaara O, et al. Bone mineral density in asthmatic women on high dose inhaled beclomethasone dipropionate. Bone 1994; 15: 621–3

    Article  PubMed  CAS  Google Scholar 

  51. Boulet L-P, Giguere M-C, Milot J, et al. Effects of long term use of high-dose inhaled steroids on bone density and calcium metabolism. J Allergy Clin Immunol 1994; 94: 796–803

    Article  PubMed  CAS  Google Scholar 

  52. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet 2000; 355: 1399–403

    Article  PubMed  CAS  Google Scholar 

  53. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001; 345: 941–7

    Article  PubMed  CAS  Google Scholar 

  54. Tattersfield AE, Town GI, Johnell O, et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax 2001; 56: 272–8

    Article  PubMed  CAS  Google Scholar 

  55. Doull IJM, Freezer NJ, Holgate ST. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995; 151: 1715–9

    PubMed  CAS  Google Scholar 

  56. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343: 1064–9

    Article  PubMed  CAS  Google Scholar 

  57. van Staa TP, Leufkens HGM, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000. 39(12): 1383–9

    Article  PubMed  Google Scholar 

  58. Baltzan MA, Suissa S, Bauer DC, et al. Hip fractures attributable to corticosteroid use [letter]. Lancet 1999; 353: 1327

    Article  PubMed  CAS  Google Scholar 

  59. McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 704–9

    PubMed  CAS  Google Scholar 

  60. Walley T, Mantgani A. The UK general practice research database. Lancet 1997; 350: 1097–9

    Article  PubMed  CAS  Google Scholar 

  61. Hubbard RB, Smith CJP, Smeeth L, et al. Inhaled corticosteroids and fracture: a population based case-control study. Am J Respir Crit Care Med 2002; 166: 1563–6

    Article  PubMed  Google Scholar 

  62. van Staa TP, Leufkens HGM, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16: 581–8

    Article  PubMed  Google Scholar 

  63. Suissa S, Baltzan M, Kremer R, et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004; 169: 83–8

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review.

Richard Hubbard has no conflict of interest. Anne Tattersfield has received grant support from AstraZeneca, speakers fees from AstraZeneca and Schering Plough and consultancy fees from Schering Plough within the last 3 years.

Author information

Authors and Affiliations

  1. Division of Respiratory Medicine, University of Nottingham, Nottingham, UK

    Richard Hubbard & Anne Tattersfield

Authors
  1. Richard Hubbard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Tattersfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Hubbard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hubbard, R., Tattersfield, A. Inhaled Corticosteroids, Bone Mineral Density and Fracture in Older People. Drugs Aging 21, 631–638 (2004). https://doi.org/10.2165/00002512-200421100-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200421100-00002

Keywords

Search

Navigation